A Cheshire based medical company Dot Medical, is the only UK Company to offer a unique life saving wearable ‘vest’ that monitors, detects and shocks people having a heart attack.
heart
Edwards Lifesciences Completes Enrollment in Non-Surgical Study Arm of U.S. Clinical Trial for Transcatheter Valve
Edwards Lifesciences Corporation, the world leader in the science of heart valves, today announced completion of enrollment in the 350-patient non-surgical study arm of its U.S. pivotal trial — known as the PARTNER Trial — for the Edwards SAPIEN transcatheter aortic heart valve.
LUMEDX and Mennen Medical® Announce Agreement for a Strategic Cooperation
LUMEDX Corporation & Mennen Medical® announced today the signing of a strategic partnership agreement to provide a total, integrated cath lab data solution and seamless stream of hemodynamic cardiovascular patient data to their customers.
Medtronic Links Device for Heart to 13 Deaths
Medtronic said Friday that at least 13 people might have died in connection with a heart device that it recalled in 2007 but was still in widespread use.
Acute myocardial infarction (AMI) successfully treated with Stentys self-expanding platform, solving stent-malapposition
Medical device pioneer Stentys announced today that it has extended its ‘self-expanding’ and ‘disconnectable’ technology platform to include a second major indication—acute myocardial infarction.
First Swiss Patients Treated With The Percutaneous MitraClip® System
Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced that the first series of patients have been successfully treated with the MitraClip® system at the Cardiocentro Ticino in Lugano, Switzerland.
Abbott Launches VOYAGER™ NC Coronary Balloon Catheter
VOYAGER™ NC Coronary Balloon Catheter is the latest Innovation in Balloon Technology, Designed to Optimize Treatment of Patients with Coronary Artery Disease
FDA Approves SyntheMed’s REPEL-CV® Adhesion Barrier for Use in Pediatric Cardiac Surgery
SyntheMed, Inc., a biomaterials company engaged in the development and commercialization of anti-adhesion products, today announced that the U.S. Food and Drug Administration has approved the Pre-market Approval application for REPEL-CV® Adhesion Barrier for use in pediatric cardiac surgery patients.
Cardiac Dimensions®, Inc. Announces Key Personnel Changes
Two important additions to Cardiac Dimension®’s senior management team. Mr. Paul Cornelison recently joined the company as Vice President of Regulatory Affairs and Quality Assurance. In addition, Mr. Nawzer Mehta, Ph.D., has joined the company as Vice President of Clinical Affairs.